It was initially observed, and is now accepted that bariatric surgery which shifts digestion of food from the upper small intestine to the lower part of small intestine (e.g. “Roux-En-Y bypass), performed for weight loss, improves Type 1 diabetes and resolves Type 2 diabetes within days in a majority of patients with diabetes. In addition, lowering of blood pressure, triglycerides, and C-reactive protein was observed (Buchwald, H. et.al; JAMA, 2004; 292:1724-1737). This typically occurs prior to significant weight loss. There is strong evidence that the mechanism of this effect results from expedited delivery to the lower gut of specific nutrients that promote secretion of gut hormones crucial for the regulation of blood glucose levels.
The following animation depicts how:
- Nutrients in food stimulate hormone responses in non-diabetic subjects
- Diabetes affects this response
- RYGB corrects the effects of diabetes
- Targeted delivery of BioKier’s capsule will mimic the effects of RYGB
BioKier has devised a proprietary oral formulation (BKR-013) that is designed to mimic the effects of metabolic surgery and improve glucose management without the physical trauma and cost of the surgery. BioKier’s approach is expected to be suitable for both obese and non-obese patients. Specifically, the treatment acts by stimulating L-cells in the lower gut with an orally delivered therapeutic, thus correcting the deficiency in secretion of endogenous GLP-1 and other gut hormones, such as PYY, GLP-2, and oxyntomodulin, that regulate glucose metabolism and appetite. Therefore, this treatment should also have potentially beneficial effects in the treatment of hypertriglyceridemia, metabolic syndrome, and obesity.